FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904146865> ?p ?o ?g. }

• W2904146865 endingPage "199" @default.
• W2904146865 startingPage "193" @default.
• W2904146865 abstract "Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis. As the degree of ovarian suppression obtained with elagolix is dose-dependent, pain relief may be achieved by modulating the level of hypo-oestrogenism while limiting side effects. Elagolix may thus be considered a novelty in terms of its endocrine and pharmacological properties but not for its impact on the pathogenic mechanisms of endometriosis, as the target of this new drug is, yet again, alteration of the hormonal milieu. Given the oestrogen-dependent nature of endometriosis, a reduction of side effects may imply a proportionate decrease in pain relief. Furthermore, if low elagolix doses are used, ovulation is not consistently inhibited, and patients should use non-hormonal contraceptive systems and perform serial urine pregnancy tests to rule out unplanned conception during periods of treatment-induced amenorrhoea. If high elagolix doses are used to control severe pain for long periods of time, add-back therapies should be added, similar to that prescribed when using GnRH agonists. To date, the efficacy of elagolix has only been demonstrated in placebo-controlled explanatory trials. Pragmatic trials comparing elagolix with low-dose hormonal contraceptives and progestogens should be planned to verify the magnitude of the incremental benefit, if any, of this GnRH antagonist over currently used standard treatments. The price of elagolix may impact on patient adherence and, hence, on clinical effectiveness. In the USA, the manufacturer AbbVie Inc. priced elagolix (OrilissaTM) at around $10 000 a year, i.e. $845 per month. When faced with unaffordable treatments, some patients may choose to forego care. If national healthcare systems are funded by the tax payer, the approval and the use of a new costly drug to treat a chronic condition, such as endometriosis, means that some finite financial resources will be diverted from other areas, or that similar patients will not receive the same level of care. Thus, defining the overall 'value' of a new drug for endometriosis also has ethical implications, and trade-offs between health outcomes and costs should be carefully weighed up." @default.
• W2904146865 created "2018-12-22" @default.
• W2904146865 creator A5012873171 @default.
• W2904146865 creator A5014325812 @default.
• W2904146865 creator A5060819005 @default.
• W2904146865 creator A5069350522 @default.
• W2904146865 creator A5073892131 @default.
• W2904146865 date "2018-12-14" @default.
• W2904146865 modified "2023-10-16" @default.
• W2904146865 title "Elagolix for endometriosis: all that glitters is not gold" @default.
• W2904146865 cites W1993456045 @default.
• W2904146865 cites W2006390573 @default.
• W2904146865 cites W2015712245 @default.
• W2904146865 cites W2039104184 @default.
• W2904146865 cites W2092177969 @default.
• W2904146865 cites W2101288911 @default.
• W2904146865 cites W2117571760 @default.
• W2904146865 cites W2118330723 @default.
• W2904146865 cites W2163315477 @default.
• W2904146865 cites W2168488550 @default.
• W2904146865 cites W2190711277 @default.
• W2904146865 cites W2269509473 @default.
• W2904146865 cites W2315060560 @default.
• W2904146865 cites W2515549381 @default.
• W2904146865 cites W2548119897 @default.
• W2904146865 cites W2583357828 @default.
• W2904146865 cites W2587854153 @default.
• W2904146865 cites W2610244466 @default.
• W2904146865 cites W2616333165 @default.
• W2904146865 cites W2626913383 @default.
• W2904146865 cites W2726576298 @default.
• W2904146865 cites W2727131837 @default.
• W2904146865 cites W2737573923 @default.
• W2904146865 cites W2761947111 @default.
• W2904146865 cites W2765144428 @default.
• W2904146865 cites W2767323643 @default.
• W2904146865 cites W2772900985 @default.
• W2904146865 cites W2773939391 @default.
• W2904146865 cites W2789651299 @default.
• W2904146865 cites W2793624162 @default.
• W2904146865 cites W2799654336 @default.
• W2904146865 cites W2804387186 @default.
• W2904146865 cites W2806866870 @default.
• W2904146865 cites W2807847822 @default.
• W2904146865 cites W2809363466 @default.
• W2904146865 cites W2887551760 @default.
• W2904146865 cites W2915078548 @default.
• W2904146865 cites W4230319391 @default.
• W2904146865 doi "https://doi.org/10.1093/humrep/dey368" @default.
• W2904146865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30551159" @default.
• W2904146865 hasPublicationYear "2018" @default.
• W2904146865 type Work @default.
• W2904146865 sameAs 2904146865 @default.
• W2904146865 citedByCount "34" @default.
• W2904146865 countsByYear W29041468652017 @default.
• W2904146865 countsByYear W29041468652019 @default.
• W2904146865 countsByYear W29041468652020 @default.
• W2904146865 countsByYear W29041468652021 @default.
• W2904146865 countsByYear W29041468652022 @default.
• W2904146865 countsByYear W29041468652023 @default.
• W2904146865 crossrefType "journal-article" @default.
• W2904146865 hasAuthorship W2904146865A5012873171 @default.
• W2904146865 hasAuthorship W2904146865A5014325812 @default.
• W2904146865 hasAuthorship W2904146865A5060819005 @default.
• W2904146865 hasAuthorship W2904146865A5069350522 @default.
• W2904146865 hasAuthorship W2904146865A5073892131 @default.
• W2904146865 hasBestOaLocation W29041468651 @default.
• W2904146865 hasConcept C126322002 @default.
• W2904146865 hasConcept C127413603 @default.
• W2904146865 hasConcept C142724271 @default.
• W2904146865 hasConcept C188198153 @default.
• W2904146865 hasConcept C204787440 @default.
• W2904146865 hasConcept C27081682 @default.
• W2904146865 hasConcept C2777702977 @default.
• W2904146865 hasConcept C2777886879 @default.
• W2904146865 hasConcept C2779522080 @default.
• W2904146865 hasConcept C46699223 @default.
• W2904146865 hasConcept C71315377 @default.
• W2904146865 hasConcept C71924100 @default.
• W2904146865 hasConcept C78519656 @default.
• W2904146865 hasConcept C98274493 @default.
• W2904146865 hasConceptScore W2904146865C126322002 @default.
• W2904146865 hasConceptScore W2904146865C127413603 @default.
• W2904146865 hasConceptScore W2904146865C142724271 @default.
• W2904146865 hasConceptScore W2904146865C188198153 @default.
• W2904146865 hasConceptScore W2904146865C204787440 @default.
• W2904146865 hasConceptScore W2904146865C27081682 @default.
• W2904146865 hasConceptScore W2904146865C2777702977 @default.
• W2904146865 hasConceptScore W2904146865C2777886879 @default.
• W2904146865 hasConceptScore W2904146865C2779522080 @default.
• W2904146865 hasConceptScore W2904146865C46699223 @default.
• W2904146865 hasConceptScore W2904146865C71315377 @default.
• W2904146865 hasConceptScore W2904146865C71924100 @default.
• W2904146865 hasConceptScore W2904146865C78519656 @default.
• W2904146865 hasConceptScore W2904146865C98274493 @default.
• W2904146865 hasIssue "2" @default.
• W2904146865 hasLocation W29041468651 @default.
• W2904146865 hasLocation W29041468652 @default.

• next